Mayne Pharma Group (MYX) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of hybrid format, procedural instructions, and commenced at 10:00am Melbourne time, chaired by Professor Bruce Robinson.

• Introduction of Board members, executives, and auditor; recognition of retiring directors and former Chair.

• Outlined meeting structure: Chair's report, CFO's business update, Q&A, and voting on resolutions.

Financial performance review

• FY25 revenue grew 5% to AUD 408.1 million, gross margin expanded to 60.6%, and underlying EBITDA more than doubled to AUD 47 million.

• Operating cash flow from continuing operations improved to AUD 45.4 million, up 460%.

• 1H FY26 unaudited revenue was AUD 212.1 million (down 0.5%), gross margin rose to 66%, and underlying EBITDA was AUD 28.6 million, down 8%.

• Women's Health segment revenue up 25% in FY25 and 2% in 1H FY26; Dermatology margin improved despite generic competition.

• International segment revenue AUD 36.9 million with improved margin and gross profit up 6%.

Board and executive committee updates

• Frank Condella retired as Chair in January 2026; Anne Lockwood and Pat Blake to retire after 1H results.

• Bruce Robinson reaffirmed commitment to strategy execution and Board stability.

• Ann Custin and David Petrie stood for re-election, highlighting their experience and commitment.

• Board comprised of Chair, non-executive directors, CEO & Managing Director, and CFO, with introductions at the start.